InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: inmodemd.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
3/29/2023 | $40.00 | Buy | UBS |
2/17/2023 | Buy → Hold | Needham | |
12/21/2022 | $44.00 | Overweight | Barclays |
10/12/2022 | $40.00 | Buy | Jefferies |
2/11/2022 | $103.00 → $82.00 | Buy | Needham |
10/27/2021 | $80.00 → $100.00 | Buy | Canaccord Genuity |
10/13/2021 | $60.00 → $80.00 | Buy | Canaccord Genuity |
10/13/2021 | $120.00 → $85.00 | Overweight | Barclays |
Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $33 to $29.
Canaccord Genuity analyst Caitlin Cronin maintains InMode (NASDAQ:INMD) with a Hold and lowers the price target from $21 to $16.
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode (NASDAQ:INMD) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.44 by 27.27 percent. This is a 38.46 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $80.28 million which missed the analyst consensus estimate of $93.02 million by 13.69 percent. This is a 24.31 percent decrease over sales of $106.07 million the same period last year.
InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe the patent. That litigation is ongoing.
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
UBS initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham downgraded InMode from Buy to Hold
Barclays initiated coverage of InMode with a rating of Overweight and set a new price target of $44.00
Jefferies initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham reiterated coverage of InMode with a rating of Buy and set a new price target of $82.00 from $103.00 previously
Canaccord Genuity reiterated coverage of InMode with a rating of Buy and set a new price target of $100.00 from $80.00 previously
Canaccord Genuity reiterated coverage of InMode with a rating of Buy and set a new price target of $80.00 from $60.00 previously
Barclays reiterated coverage of InMode with a rating of Overweight and set a new price target of $85.00 from $120.00 previously
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2024 before the Nasdaq market opens on Thursday, Aug. 1, 2024. InMode is currently finalizing its financial res
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: Quarterly GAAP revenue of $80.3 million, a decrease of 24% compared to the first quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 84% of its quarterly revenues, while 11% were derived from InMode's traditiona
Expects Q1 Revenue Between $80.0M-$80.1M, Pro Forma Revenue (including new platform pre-orders) Between $95.7M- $95.8M, Decreases FY 2024 Guidance to $485M-$495M Conference call to be held on Thursday, May 2, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 9, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024. InMode is currently finalizing its financial results for the first quarter of 2024. While complete financial information and operating data are not yet available, set
YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Quarterly revenue of $126.8 million, compared to $133.6 in the fourth quarter of 2022.Quarterly revenues from consumables and service of $20.5 million, an increase of 20% compared to the fourth quarter of 2022.Total cash position of $741.6 million as of December 31, 2023, including cash and cash equivalents, marketable securities, and short-term bank deposits.Full Year 2023 Highlights: Record full year r
Conference call to be held on Tuesday, February 13, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2023 before the Nasdaq market opens on Tuesday, February 13, 2024. InMode is currently finalizing its financial results for the fourth quarter and full year of 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary financial results for said period, subject to final adjustments and other developments that
Conference call to be held on Thursday, Nov. 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 12, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2023 before the Nasdaq market opens on Thursday, Nov. 2, 2023. InMode is currently finalizing its financial results for the three months ended Sept. 30, 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary financial results for such period, subject to final adjustments and further review as well as other developments t
YOKNEAM, Israel, July 27, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights: Record quarterly revenue of $136.1 million, an increase of 20% compared to the second quarter of 2022. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 81% of quarterly revenues, while 9% came from InMode's hands-free platforms and 10% from InMode's traditional laser and non-invasive RF platforms.Record GAAP net income of $55.7 million, compared
Conference call to be held on Thursday, July 27, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 12, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2023 before the Nasdaq market opens on Thursday, July 27, 2023. InMode is currently finalizing its financial results for the three months ended June 30, 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that m
YOKNEAM, Israel, May 2, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights: Quarterly revenue of $106.1 million, an increase of 23.5% compared to the first quarter of 2022. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 83% of quarterly revenues, while 8% came from InMode's hands-free platforms and 9% from InMode's traditional laser and non-invasive RF platforms.GAAP net income of $40.5 million, compared to $31 million in
Conference call to be held on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 12, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2023 before the Nasdaq market opens on Tuesday, May 2, 2023. InMode is currently finalizing its financial results for the three months ended March 31, 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may
IRVINE, Calif., July 17, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce an additional FDA 510(k) clearance for the Morpheus8 technology. Morpheus8 is the first and only fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The U.S. Food and Drug Administration (FDA) has cleared the use of the Morpheus8 Applicators for the delivery of fractional radiofrequency use in dermatologic skin procedures where coagulation/contraction of soft tissue or hemostas
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2024 before the Nasdaq market opens on Thursday, Aug. 1, 2024. InMode is currently finalizing its financial res
YOKNEAM, Israel, May 16, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Jefferies Healthcare Conference in New York on June 5, 2024. The fireside chat, moderated by Matt Taylor, Managing Director, Senior Healthcare Analyst, is scheduled for 7:30 am Eastern Time on Wednesday, June 5 and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Jefferies representative. For more info
IRVINE, Calif., May 8, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with P1 Offshore Racing and sponsor the only female driver, Victoria Rand, as part of Class 1. This partnership signifies a historic step forward in motorsports, and reflects InMode's unwavering dedication to championing and empowering women. Victoria Rand, hailing from Denmark with a lineage deeply rooted in racing, brings an unparalleled passion for speed and competition in traditional motors
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: Quarterly GAAP revenue of $80.3 million, a decrease of 24% compared to the first quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 84% of its quarterly revenues, while 11% were derived from InMode's traditiona
YOKNEAM, Israel, April 15, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency based feminine rejuvenation products infringe the patent. That litigation is ongoing.
Expects Q1 Revenue Between $80.0M-$80.1M, Pro Forma Revenue (including new platform pre-orders) Between $95.7M- $95.8M, Decreases FY 2024 Guidance to $485M-$495M Conference call to be held on Thursday, May 2, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 9, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024. InMode is currently finalizing its financial results for the first quarter of 2024. While complete financial information and operating data are not yet available, set
YOKNEAM, Israel, April 3, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in April and May: 23rd Annual Needham Virtual Healthcare ConferencePresenters: Moshe Mizrahy, Chief Executive Officer and Chairman, Yair Malca, Chief Financial Officer and Spero Theodorou, Chief Medical OfficerFormat: Virtual fireside chat moderated by Michael Matson, CFA and Senior Equity Research Analyst and one-on-one meetingsWhen: Tuesday, April 9 at 8:00 am
YOKNEAM, Israel, March 4, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in March: Oppenheimer 34th Annual Healthcare MedTech & Services Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Chairman Format: Virtual fireside chat moderated by Suraj Kalia, Managing Director, Med Device Research Analyst, and one-on-one meetings When: Tuesday, March 12 at 8:00 am ET A live webcast of the presentation can be accessed here. 2024 Barclays Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer, and Dr. Spero Theodorou,
YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Quarterly revenue of $126.8 million, compared to $133.6 in the fourth quarter of 2022.Quarterly revenues from consumables and service of $20.5 million, an increase of 20% compared to the fourth quarter of 2022.Total cash position of $741.6 million as of December 31, 2023, including cash and cash equivalents, marketable securities, and short-term bank deposits.Full Year 2023 Highlights: Record full year r
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
20-F - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)